By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS


Industry
Biotechnology






Company News
Janssen-Cilag International NV (JNJ) Receives CHMP Positive Opinion For STELARA (Ustekinumab) Recommending Approval For The Treatment Of Moderately To Severely Active Crohn’s Disease In The European Union 9/16/2016 8:12:39 AM
Janssen-Cilag International NV (JNJ) Submits Application To EMA To Expand Use Of DARZALEX (Daratumumab) To Include Combination With Standard Of Care Regimens 8/23/2016 9:40:30 AM
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016 11:01:13 AM
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016 10:46:41 AM
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016 8:41:16 AM
ASCO2016: Janssen-Cilag International NV (JNJ) Release: New Data Reveal That Presence Of Metastases At Initial Prostate Cancer Diagnosis May Have A Critical Impact On Prognosis For Metastatic Castration-Resistant Patients 6/6/2016 1:52:50 PM
Janssen-Cilag International NV (JNJ)’s IMBRUVICA (Ibrutinib) Approved By European Commission For Patients With Newly Diagnosed Chronic Lymphocytic Leukaemia 5/31/2016 12:57:41 PM
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves TREVICTA (Paliperidone Palmitate A 3-Monthly Injection), For Maintenance Treatment Of Schizophrenia 5/31/2016 11:28:04 AM
Janssen-Cilag International NV (JNJ)’s Single-Agent DARZALEX (daratumumab) Approved By European Commission For Treatment OIf Multiple Myeloma (MM) 5/23/2016 9:33:12 AM
Janssen-Cilag International NV (JNJ)’s IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion For Expanded Use In Previously Untreated Chronic Lymphocytic Leukaemia Patients 4/29/2016 10:12:50 AM
123456
//-->